On Wednesday, August 28, 2019 at 8:00 PM EDT, the Meso Foundation’s Meet the Mesothelioma Experts live broadcast will feature Drs. Dan Sterman of NYU and Steve Albelda of the University of Pennsylvania. The focus of the interview will be their new Phase 3 gene therapy clinical trial evaluating the efficacy and safety of intrapleural administration of adenovirus-delivered interferon Alpha-2b (rAd-IFN) in combination with celecoxib and gemcitabine in patients with malignant pleural mesothelioma.
This live broadcast is open and appropriate for all members of the mesothelioma community including patients, families, medical professionals and anyone else interested in learning more. There is no charge, but we do ask that you RSVP in order to receive the call-in phone number.
This live broadcast is made possible by an educational grant by Trizell Ltd.
About the Speakers
Dr. Albelda is a pulmonologist at the University of Pennsylvania. His research goal is to develop novel approaches to the treatment of lung cancer and mesothelioma, with special emphasis on gene and immunotherapy.
Dr. Sterman is a pulmonologist at NYU. Over the past 22 years, he has focused on the translation of laboratory discoveries from the bench to the bedside: conducting multiple Phase I human clinical trials of gene therapy and vaccine therapy for lung cancer, mesothelioma, and other pleural malignancies. Dr. Sterman’s current interests include immunophenotyping of lymph nodes in thoracic malignancies, and development of novel intranodal, intratumoral, and intrapleural therapies as adjuncts to systemic checkpoint inhibition in lung cancer and mesothelioma.
As part of the Meet the Mesothelioma Experts (MTME) series, the Meso Foundation invites specialists in the field of mesothelioma to discuss their current research interests as well as promising developments in the treatment of mesothelioma.
Interested in participating in our MTME as a guest speaker? Contact us at [email protected] or 703-879-3797.
